Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16.
Adult T cell leukemia/lymphoma (ATLL) induced by human T cell leukemia virus I is resistant to conventional therapy. Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). Two patients achieved complete remission, lasting 12 months and more than 8 months, and 2 others partial remission, lasting 2 months and 6 weeks, respectively. The major toxicity was myelosuppression. Other toxicities were not severe and were well tolerable. Orally administered MST-16 is a promising agent for the treatment of ATLL.
Ichihashi
T
T
Department of Medicine, Branch Hospital, Nagoya University School of Medicine, Japan.
Kiyoi
H
H
Fukutani
H
H
Kubo
K
K
Yamauchi
T
T
Naoe
T
T
Yamada
K
K
Ohno
R
R
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D010879:Piperazines; C057773:sobuzoxane